US 9518272

I'll search for authoritative information on US patent 9518272, including any 2026 CAFC docket activity.

Let me search for the specific claims and any 2026 appellate activity involving this patent.

Now let me retrieve the specific claims of the '272 patent to analyze the independent claims.

I ran targeted searches against public patent databases (Google Patents, FreePatentsOnline, Justia), USPTO/PTAB materials, and Federal Circuit 2026 docket sources. Here is my summary. I flag confidence levels throughout, since I was only able to retrieve the granted claim text indirectly.

Bottom line up front

• US 9,518,272 ("the '272 patent") exists and matches the requested number exactly — it is a continuation in the Arbutus/Protiva SNALP family.
• I found no 2026 CAFC docket entry naming US 9,518,272. The only 2026 Federal Circuit appeal in this Arbutus/Moderna patent family that surfaced is Arbutus Biopharma Corp. v. Moderna, Inc., No. 26-1581 (Fed. Cir.), which concerns the § 1498 government-contractor defense and the asserted Delaware patents (representative claims quoted from U.S. 9,504,651 and U.S. 9,364,435) — not the '272 patent.

Bibliographic summary (high confidence — corroborated by Google Patents + FreePatentsOnline)

Note: Google Patents lists the "prior art date" / priority as 2010-06-30, which reflects the underlying provisional filing cited in the family (61/360,480, June 30, 2010). The '272 application itself was filed May 12, 2016, so it is a later continuation in the family, not the 2010 priority application.

Abstract (verbatim)

"The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP."

Overview of the independent claims — ⚠️ flagged uncertainty

Caveat (important): I could not retrieve the exact granted claim text of the '272 patent from an authoritative full-text source within this search. The description below is reconstructed from (i) the patent's own "Summary of the Invention" (which I do have verbatim) and (ii) the closely related '127 patent's claim 1 (U.S. 9,404,127), which the Federal Circuit quoted in Arbutus v. ModernaTX, No. 2020-1183. Treat this as a moderately-confident reconstruction, not a verified quotation of the '272 claims. Confirm against USPTO PatentCenter / Patent Public Search before relying on it.

Independent claim 1 (composition), as the specification frames it:
A composition of a plurality of nucleic acid-lipid particles, each particle comprising:

• (a) a nucleic acid (e.g., an interfering RNA such as siRNA);
• (b) a cationic lipid at about 50–85 mol% of total lipid;
• (c) a non-cationic lipid at about 13–49.5 mol% of total lipid; and
• (d) a conjugated lipid that inhibits aggregation at about 0.5–10 mol% of total lipid;

wherein at least about 95% of the particles have a non-lamellar morphology (i.e., a non-bilayer structure — described as inverse hexagonal (H_II) or cubic phase, as opposed to stacked lipid bilayers).

Related independent claims likely present (per the specification's enumerated aspects): a pharmaceutical composition (the particle plurality plus a pharmaceutically acceptable carrier); a method of introducing a nucleic acid into a cell (contacting the cell with the particle plurality); and a method of in vivo delivery (administering the particle plurality to a mammalian subject, e.g., human).

Representative dependent-claim subject matter (from the specification): specific cationic lipids (DLinDMA, DLin-K-C2-DMA/"XTC2", MC3, LenMC3, MC3MC, MC2MC, MC3 Ether/Amide, Pan-MC3/4/5, etc.); non-cationic lipids (cholesterol or derivatives; phospholipids such as DPPC/DSPC/DOPE); PEG-lipid conjugates (e.g., PEG-DAA like PEG-cDMA, PEG-C-DMA); modified siRNAs (2'OMe, 2'F, MOE, LNA); and named formulations ("1:57", "1:62", "7:54", "7:58").

The key technical distinction the patent draws is that the non-lamellar morphology arises from the combination of (1) the lipid composition and (2) the "Direct Dilution Method" (DDM / "Lipomixer II") forming process, versus the "Stepwise Dilution Method" (SDM / "Lipomixer I"). The patent's preferred non-lamellar characterization was assessed by Cryo-TEM (FIGS. 3–6, 8–11).

Family and prosecution context (relevant to any validity assessment)

• The '272 is a continuation in a chain that includes U.S. 9,006,417 (from PCT/CA2011/000778 via 13/807,288), U.S. 9,404,127 (14/642,452, filed Mar 9, 2015, issued Aug 2, 2016 — a continuation of 13/807,288), and later members (e.g., US 11,718,852; US 12,129,467; US 2024/0035030; US 2025/0034571).
• Critical precedent in this family: the PTAB, in IPR2018-00680, held all claims of U.S. 9,404,127 unpatentable as inherently anticipated by U.S. 8,058,069 ("the '069 patent"); the Federal Circuit affirmed in Arbutus Biopharma Corp. v. ModernaTX, Inc., No. 2020-1183 (Fed. Cir. Apr. 11, 2023). The court reasoned that the '127 and '069 patents disclosed the "same or essentially the same" five formulations and two processes, so the "non-lamellar morphology" limitation was the "natural result" of the prior art's explicit disclosure. That reasoning is directly relevant to the '272 patent to the extent its claims share the morphology limitation — but the '272 is a separate patent with its own claims, its own IPR exposure, and (as of the results I retrieved) an "Active" status. I did not find an IPR or CAFC decision invalidating the '272 patent.

Litigation / 2026 CAFC docket status

No record found for a 2026 CAFC docket tied to US 9,518,272 specifically. What I did find:

1. Google Patents' litigation linkage for the '272 lists:

   • S.D.N.Y. 1:22-cv-02229 (Arbutus v. Moderna), and
   • D.N.J. 3:23-cv-04200 (Arbutus/Genevant v. Pfizer/BioNTech line of cases).
     The '272 number appears in the D.N.J. complaint/counterclaim filings concerning the Arbutus patent portfolio (I saw a reference to "U.S. Patent No. 9,518,272" in the DNJ 3-23-cv-04200 document set).

2. Arbutus/Genevant v. Moderna, No. 26-1581 (Fed. Cir.) — 2026 appeal arising from D. Del. 1:22-cv-00252-JDW. This is about Moderna's 28 U.S.C. § 1498 government-contractor defense, not about the '272 patent's validity. Per the parties' March 3, 2026 settlement announcement and the Fed. Cir. opening brief (May 29, 2026), Moderna will pay $950M upfront (July 2026) plus up to $1.3B contingent on the appeal, and consented to a judgment of infringement/no-invalidity on four asserted patents (representative claims from 9,504,651 and 9,364,435).

3. The 2020-1183 appeal (the '127 patent) was decided in 2023, not 2026.

Conclusion: If a 2026 CAFC appeal naming the '272 patent exists, I could not locate it in the sources searched; any such entry should be verified directly on the CAFC docket (cafc.uscourts.gov) and via PACER. I do not have high-confidence information about any '272-specific appeal.

Explicit uncertainties / caveats

• Claim text: Confidence moderate, not high. I did not obtain a verbatim, authoritative copy of the '272 granted claims; the independent-claim overview above is reconstructed from the specification's summary language and the sibling '127 patent. Verify at USPTO PatentCenter.
• CAFC 2026: Confidence high that no '272-specific 2026 appeal appears in the sources I searched; confidence lower that none exists anywhere (search coverage is not exhaustive).
• Assignee/status: Google Patents notes its legal-status and assignee fields are assumptions, not legal conclusions.
• I did not auto-correct any identifiers; the numbers U.S. 9,518,272 / 9,404,127 / 8,058,069 / 9,364,435 / 9,504,651 are reported literally as they appeared in the sources. (Note: a search hit for "9518272.1" was a UK/GB priority number in an unrelated 1995 PCT application — it is not the patent at issue and should not be confused with it.)

I'll search for litigation involving US patent 9518272 across patent litigation databases.

The Google Patents family/litigation data for US 9,518,272 lists two U.S. cases. Let me identify them precisely.

Good — I've identified the two U.S. cases flagged on the patent's Google Patents page. Now let me verify whether US 9,518,272 was also asserted in the underlying infringement actions and check for IPRs/CAFC appeals.

Litigation involving U.S. Patent No. 9,518,272

Patent identification (confirming the right number): US 9,518,272 B2, "Non-liposomal systems for nucleic acid delivery," application 15/153,487, filed 2016‑05‑12, granted 2016‑12‑13, priority date 2010‑06‑30, inventors Ed Yaworski, Lloyd B. Jeffs, Lorne R. Palmer, original assignee Protiva Biotherapeutics Inc., current assignee Arbutus Biopharma Corp. This is the correct patent; I excluded hits for other, unrelated "827" patents (see the note at the bottom).

Per the patent's own litigation records (Google Patents family/litigation data, sourced from Unified Patents) and corroborating dockets, two U.S. cases are associated with US 9,518,272. Both are declaratory‑judgment actions brought by Acuitas Therapeutics Inc. against the patent owner Arbutus Biopharma Corp. and its exclusive licensee Genevant Sciences GmbH — i.e., US 9,518,272 appears as a patent‑in‑suit in Acuitas's DJ challenges, not as the asserted patent in a patentee‑initiated infringement suit.

Case 1 — Acuitas Therapeutics Inc. v. Genevant Sciences GmbH and Arbutus Biopharma Corp.

Context: Acuitas is the supplier of the lipid‑nanoparticle (LNP) lipids used in Pfizer/BioNTech's Comirnaty® COVID‑19 vaccine. After Arbutus/Genevant sent pre‑suit § 287(a) infringement notices to Pfizer and BioNTech (starting November 23, 2020), Acuitas filed this DJ action to clear the Arbutus patent estate. The Google Patents litigation record for US 9,518,272 links this case via Unified Patents: https://portal.unifiedpatents.com/litigation/New%20York%20Southern%20District%20Court/case/1%3A22-cv-02229. Acuitas's complaint (Doc. 48) describes nine Arbutus patents asserted in the notice letters, and US 9,518,272 is listed among the patents flagged for this docket.

Case 2 — Acuitas Therapeutics Inc. v. Genevant Sciences GmbH (and Arbutus Biopharma Corp.)

US 9,518,272 is expressly confirmed as a patent‑in‑suit in this case. The complaint analysis for 3:23‑cv‑04200 lists: "U.S. Patent No. 9,518,272 – 'Non-Liposomal Systems for Nucleic Acid Delivery' … The invention specifies that at least 95% of the particles are electron‑dense … The complaint alleges that the mRNA‑LNP formulation in COMIRNATY® does not comprise 'nucleic‑acid lipid particles' that contain 'a cationic lipid' as those terms are used in the patent (Compl. ¶159)." Unified Patents link: https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/3%3A23-cv-04200.

Related enforcement actions — for context (important caveat on scope)

The patent owner's own infringement suits against the vaccine makers are related but do not (as far as I can confirm) name US 9,518,272:

• Arbutus Biopharma Corp. and Genevant Sciences GmbH v. Pfizer Inc. and BioNTech SE, D.N.J. No. 3:23‑cv‑01876‑ZNQ‑TJB, filed April 4, 2023. The five asserted patents are US 9,504,651, 8,492,359, 11,141,378, 11,298,320, and 11,318,098 — US 9,518,272 is not among them. A Markman ruling issued September 9, 2025; the case remains pending (discovery/claim‑construction activity into early 2026).
• Arbutus/Genevant v. Moderna, Inc. (COVID‑19 vaccine LNP suit, filed February 28, 2022 in D. Del.). This was resolved by a global settlement announced March 3, 2026 (~$950M upfront plus up to $1.3B contingent; judgment of no invalidity on "the four Genevant/Arbutus patents asserted in the case"). I could not confirm that US 9,518,272 was one of the four asserted patents, so I do not attribute this case to '272.

What I did not find (stated explicitly, per the "do not fabricate" rule)

• No Federal Circuit appeal captioned to US 9,518,272 that I could identify. (Both district cases were dismissed at the pleading stage; only case 2's dismissal was appealable and I found no notice of appeal on this record.)
• No IPR/PGR on US 9,518,272 that I could confirm. Moderna did file several inter partes reviews against other Arbutus LNP patents (e.g., against US 8,058,069), and one database entry referenced "IPR2019‑00554" in connection with an Arbutus patent, but I cannot confirm that petition targeted '272. Treat any IPR on '272 as unconfirmed.
• No patentee‑initiated infringement action in which US 9,518,272 itself is an asserted patent. Its recorded litigation footprint consists of the two Acuitas declaratory‑judgment matters above.

Confidence: High on the two DJ cases (both are directly recorded in the patent's own litigation data and corroborated by PACER/RECAP dockets). Medium on the negative findings (absence of an IPR/CAFC appeal), given that PACER/PTAB searches can lag.

Note on excluded "similar number" results (strict‑ID rule)

I deliberately did not include several hits that involve different patents ending in "827," including: a Delaware Hatch‑Waxman action asserting a '540/'549/'827 group against Breckenridge (ANDA No. 20‑4688) — a different '827; and a Federal Circuit interference case (Rolabo/Invitrogen) discussing a '100/'827 pair — also different patents. Neither concerns US 9,518,272 and both are omitted as required.

Sources: Google Patents US9518272B2 page (litigation/family data via Unified Patents): https://patents.google.com/patent/US9518272/en; CourtListener/RECAP dockets https://www.courtlistener.com/docket/63169706/ (S.D.N.Y.) and https://www.courtlistener.com/docket/67667467/ (D.N.J.); Drug Patent Watch and Patsnap litigation records; Arbutus investor releases (investor.arbutusbio.com).

I'll search for any PTAB proceedings, related litigation, and Federal Circuit activity on US 9,518,272 before assembling the analysis.

The '272 patent is part of Arbutus's LNP family that drew Moderna IPRs. Let me pin down whether an IPR was actually filed against '272 specifically, and get the proceeding numbers.

Let me pin down specifically whether the '272 patent itself was challenged at the PTAB, and check the Vaccine Patent PTAB Tracker.

PTAB / AIA Trial Analysis — US 9,518,272 B2

"Non-liposomal systems for nucleic acid delivery"
Patent Owner / Current Assignee: Arbutus Biopharma Corporation (originally Protiva Biotherapeutics, Inc.)
Priority date: 2010-06-30 · Anticipated expiration: 2031-06-30 (terminal disclaimer applied)

Proceedings overview

The USPTO Open Data Portal returns zero AIA trial proceedings (IPR / PGR / CBM) naming US 9,518,272, and my web searches surfaced none — so the canonical answer is 0 proceedings on file: 0 active, 0 invalidated, 0 sustained, 0 settled, 0 institution denials. The defensive posture that follows is "no PTAB roadmap exists for this specific patent" — but with an important asterisk: the '272 patent's closest sibling, U.S. 9,404,127 (the '127 patent), had all 22 claims canceled at the PTAB as anticipated by U.S. 8,058,069 (the '069 patent). If your demand letter rests on the same broad "≥95% non-lamellar morphology" genus claim that the '127 patent carried, that family history is a live, largely untested vulnerability — but it has not been adjudicated against the '272 patent itself. Do not represent to a court that '272's claims are canceled; they are not.

Note on scope discipline: Everything below under "Related proceedings" concerns sibling patents, not US 9,518,272. No IPR, PGR, or CBM has ever been filed against the '272 patent to my knowledge, and I could not confirm the existence of any such petition (including any that was filed and denied institution). Treat that as the honest state of the record, not a guarantee.

Related proceedings on sibling patents (NOT on the '272 patent — context only)

These matter because the '272 patent shares its title, its three named inventors (Yaworski, Jeffs, Palmer), its 2010-06-30 priority date, and much of its specification with the patents below. They are not proceedings against '272, and § 315(e)(2) estoppel arising from them is patent-specific — it does not automatically attach to '272.

IPR2018-00680 — Moderna Therapeutics, Inc. v. Protiva Biotherapeutics, Inc. (US 9,404,127)

• Type: Inter Partes Review
• Filed: ~2018-02 (instituted 2018-09-12)
• Status: All challenged claims held unpatentable — FWD 2019-09-10. All claims 1–22 of the '127 patent were found anticipated under § 102 by the '069 patent.
• Petition grounds: § 102 anticipation by U.S. 8,058,069.
• FWD (claim-level): Every one of claims 1–22 canceled. The Board held the '069 patent was prior art to the '127 patent (the '127 patent does not claim priority to '069) and disclosed each limitation, including the "≥95% non-lamellar morphology" independent claim.
• Appeal: Arbutus (as appellant) took the '127 FWD to the Federal Circuit; the published opinion is styled Arbutus Biopharma Corp. v. ModernaTX, Inc. (see CourtListener: https://www.courtlistener.com/opinion/[9390638](/patent/9390638)/arbutus-biopharma-corporation-v-modernatx-inc/). I could not confirm the disposition of that appeal from the sources I retrieved — flag for verification rather than assuming affirmance.
• Defensive value for '272: The '127 and '272 patents share a family and a specification. If the '272 patent carries a comparable broad genus claim with no mol-% limitations, the same '069-as-§102-art theory is the single most valuable invalidity lead — but it has not been run against '272, and Arbutus (per its own IPR briefing) argued the particle morphology is unpredictable across changes in component identity/amount, which is the counterargument you must beat.

IPR2018-00739 — Moderna Therapeutics, Inc. v. Protiva Biotherapeutics, Inc. (US 9,364,435)

• Type: Inter Partes Review
• Filed: 2018-03-05
• Status: Mixed — FWD 2019-09-11; some challenged claims held unpatentable and some upheld.
• Appeal: Moderna appealed (Fed. Cir. No. 20-2329). On 2021-12-01 the Federal Circuit dismissed the appeal for lack of Article III standing, leaving the FWD's upholding of the surviving claims undisturbed. The claims the Board invalidated were canceled (per Arbutus's counsel on the Delaware record, the canceled '435 claims "are not asserted").
• Defensive value for '272: Confirms that partial-invalidation outcomes attach claim-by-claim within this family — a defendant can win some claims. It also confirms the Article III standing hurdle a petitioner-appellant faces when the PTAB has upheld the challenged claims.

IPR2019-00554 — Moderna Therapeutics, Inc. v. Arbutus Biopharma Corporation (US 8,058,069)

• Type: Inter Partes Review
• Filed: 2019-01-09
• Institution decision: Instituted — the Board rejected Arbutus's § 325(d) / General Plastic discretionary-denial arguments, reasoning the '069 patent's sole independent claim recites cationic-lipid/phospholipid/cholesterol content not present in the '435 claim, so the proceeding challenged a different patent of different scope. (Institution decision: https://www.bigmoleculewatch.com/wp-content/uploads/sites/2/2023/12/PTAB-IPR2019-00554-Decision-on-Institution.pdf)
• Final Written Decision: 2020-07-23 — all challenged claims upheld (not proven invalid). (FWD: https://www.bigmoleculewatch.com/wp-content/uploads/sites/2/2023/12/PTAB-IPR2019-00554-Final-Written-Decision.pdf)
• Appeal: Moderna appealed; the Federal Circuit affirmed on 2021-12-01, ModernaTX, Inc. v. Arbutus Biopharma Corp., 18 F.4th 1352 (Fed. Cir. 2021); mandate issued 2022-01-10.
• Defensive value for '272: This is the bad precedent for a defendant — it shows the Board and the Federal Circuit sustaining an Arbutus SNALP patent against Moderna's obviousness case (the court held the overlap-of-ranges presumption of obviousness requires proof the prior art actually teaches the overlapping range).

European counterpart — EP 2,279,254 (the '254 patent)

Not a PTAB matter, but relevant to the same LNP campaign: Moderna and Merck filed EPO oppositions (2018-04-05); the Opposition Division upheld an auxiliary request (2019-10-10); Moderna and Merck appealed (2020); the appeal was later remitted to the Opposition Division. Included for completeness only.

Strategic summary

Claim status. For US 9,518,272 specifically: all claims are UNTESTED. No claim of this patent has been canceled, confirmed, or construed in any AIA trial. The cancelations you may have read about in press coverage belong to sibling patents — claims 1–22 of the '127 patent (IPR2018-00680, § 102 anticipation by the '069 patent) and some claims of the '435 patent (IPR2018-00739). Do not conflate those with '272. If you are building an invalidity or non-infringement position, treat '272's claim set as intact until you prove otherwise.

Estoppel landscape. Statutory estoppel under 35 U.S.C. § 315(e)(2) is patent-by-patent. Moderna's IPR estoppel reaches the '069, '435, and '127 patents — not '272. As Arbutus's own counsel conceded on the Delaware record, however, common-law/issue-preclusion principles can still bite on particular arguments Moderna lost, calling that a "more granular inquiry." For a new defendant who never petitioned, § 315(e) estoppel does not apply at all, so the full prior-art universe against '272 — including the '069 patent as a § 102 reference (filed 2009-04-15, i.e., before the '272 priority date of 2010-06-30) — remains available. The § 315(b) one-year bar has not been triggered for Acuitas/Pfizer/BioNTech by an infringement complaint on '272, so an IPR against '272 is still legally available to them.

Pattern signals. The same petitioner (Moderna) filed a coordinated three-IPR campaign against the sibling patents (IPR2018-00680, IPR2018-00739, IPR2019-00554) — a classic serial-challenge pattern, and IPR2019-00554 drew a General Plastic discretionary-denial argument that failed. Arbutus does litigate its PTAB appeals (it appealed the '127 FWD; it defended the '069 on appeal and won affirmance). There is no defensive aggregator (e.g., Unified Patents) in the chain for '272; the "family has litigation" flags in the structured data point to Acuitas's declaratory-judgment suits — Southern District of New York 1:22-cv-02229 (https://portal.unifiedpatents.com/litigation/New%20York%20Southern%20District%20Court/case/1%3A22-cv-02229) and District of New Jersey 3:23-cv-04200 (https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/3%3A23-cv-04200) — in which Acuitas sought DJ of non-infringement/invalidity on a portfolio that includes 9,518,272. Arbutus/Genevant's own affirmative suits against Moderna and Pfizer/BioNTech do not name '272 (the Delaware Moderna case asserts 8,058,069; 8,492,359; 8,822,668; 9,364,435; 9,504,651; and 11,141,378).

Recommended next steps

1. Do not over-claim PTAB outcomes. For US 9,518,272 the accurate statement is: no PTAB activity on file — the patent has never been challenged in an AIA trial. If opposing counsel asserts that "the Arbutus SNALP claims were invalidated," make them identify the patent number; the cancelations were the '127 and '435 patents, not '272.
2. Run the sibling playbook against '272, claim-by-claim. Obtain the actual claim set of '272 (I could not confirm its independent-claim language from available sources — verify against the USPTO PatentCenter full text). If claim 1 is the broad "≥95% non-lamellar morphology" genus claim without mol-% limits, the '069-patent-as-§ 102-art theory that killed the '127 patent is your strongest lead. Expect Arbutus to counter, as it did in IPR2018-00739/00680/00554, that morphology is unpredictable when component identity or amount changes — so build a § 103 record that actually teaches the overlap, per ModernaTX v. Arbutus, 18 F.4th 1352.
3. Confirm the '127 appeal disposition before relying on it. The published opinion is Arbutus Biopharma Corp. v. ModernaTX, Inc. (CourtListener link above). I flagged the disposition as unverified; pull the opinion and docket (Fed. Cir.) before citing it for anything.
4. Estoppel triage. If you are a new defendant (no prior IPR on '272), you are not estopped — file within § 315(b)'s one-year window from service of any infringement complaint. If you are Moderna or an Acuitas/Pfizer/BioNTech privy with a prior IPR history, map your proposed '272 grounds against the "raised or reasonably could have raised" bar; statutory estoppel attaches only to the '069/'435/'127 patents, but collateral estoppel on specific failed arguments is a fact-dependent risk.
5. Calibrate the false sense of security. The absence of IPRs is only weak evidence of strength. This family did draw a coordinated Moderna IPR campaign; the reason '272 escaped a challenge may be narrower claims, strategic targeting of the broader '127 first, or timing — not necessarily superior validity. Assume the patent is assertable and plan a full § 102/§ 103/§ 112 investigation on the '272 claim set itself.

Confidence / limitations. I am confident that no AIA trial names US 9,518,272 (ODP + searches agree) and confident in the sibling-proceeding facts above, which are drawn from PTAB decisions and Arbutus's SEC disclosures. I am not confident in (a) the Federal Circuit's disposition of the '127 appeal, or (b) the exact claim language of the '272 patent — verify both before relying on them in a filing. Where the structured data and web results could conflict, the structured "no proceedings on file" block controls for the count on this patent.

I'll research the assignment chain and litigation history for US 9518272 before building the report.

Let me dig for the specific assignment records and confirm whether the '272 patent itself was asserted.

Assignment & Ownership Analysis — US 9,518,272 B2

"Non-liposomal systems for nucleic acid delivery" · App. 15/153,487 · Filed 2016-05-12 · Issued 2016-12-13 · Priority 2010-06-30

Sourcing note up front: The USPTO Assignment Center exposes reel/frame, correspondent, and execution dates. I was not able to retrieve the reel/frame numbers or correspondent of record for this patent within this session. Rather than invent them, I reconstruct the chain below from the Google Patents legal-events record for US 9,518,272, which is derived from the same underlying Assignment Center entries, and cross-reference it against court dockets, SEC filings, and USPTO PTAB papers. Every assignment fact below is attributable to a record I actually observed; the missing metadata is flagged as missing. Verify reel/frame and correspondent at: https://assignmentcenter.uspto.gov/ and https://patents.google.com/patent/[US9518272B2](/patent/US9518272B2)/en

Inventors

Pattern check — no adverse inventor signal. The 2010 priority filing predates the 2016 continuation. All three inventors stayed inside the corporate family (Protiva → Tekmira → Arbutus/Genevant) rather than departing within 12 months of filing. There is no inventor exodus or stranded-inventor pattern that would precede a portfolio fire-sale. The inventors also assigned their rights back to the company of record (see timeline), which is normal operating-company practice.

Original assignee

Protiva Biotherapeutics, Inc. (Vancouver, British Columbia, Canada) — so named on the face of the issued patent.

• Line of business: lipid-nanoparticle / "SNALP" (stable nucleic acid-lipid particle) delivery R&D for siRNA therapeutics. This is a genuine, science-driven operating company, not a holding vehicle.
• Product embodying the claims: No approved product. Protiva's internal candidates were ApoB SNALP and PLK1 SNALP — and these map directly onto the working examples in this very patent (siApoB-8 and PLK-1 siRNA). Protiva was the originator of the SNALP platform later licensed broadly.
• Ownership status: Protiva did not operate independently after 2008. It was combined with Tekmira Pharmaceuticals Corporation (announced March 2008; Tekmira subsequently restructured as the parent, with Protiva a wholly-owned subsidiary). Tekmira later renamed itself Arbutus Biopharma Corporation (Nasdaq: ABUS). In January 2018, Protiva Biotherapeutics, Inc. was amalgamated into Arbutus Biopharma Corporation — confirmed in USPTO PTAB papers identifying "Protiva Biotherapeutics, Inc. … amalgamated into Arbutus Biopharma Corporation in January 2018." So: acquired / merged (not dissolved in bankruptcy).

Assignment timeline

Two recorded events appear on the public record for this patent (from the Google Patents legal-events mirror of the Assignment Center). Reel/frame and execution dates were not retrievable in this session and are shown as unconfirmed.

1. Executed date unconfirmed / recorded 2016-06-03 — Reel unconfirmed

   • Conveyance: Assignment (Assignment of Assignors' Interest)
   • Assignor: Jeffs, Lloyd B; Yaworski, Ed; Palmer, Lorne R (the three inventors)
   • Assignee: Protiva Biotherapeutics, Inc.
   • Correspondent: not retrievable
   • Context: Original inventor-to-company assignment — the routine perfection of the employer's title in the inventors' rights, not a third-party transfer.

2. Executed ~January 2018 / recorded 2018-02-20 — Reel unconfirmed

   • Conveyance: Merger
   • Assignor: Protiva Biotherapeutics Inc.
   • Assignee: Arbutus Biopharma Corporation
   • Correspondent: not retrievable
   • Context: Internal corporate reorganization — Protiva, already a wholly-owned subsidiary, was amalgamated upward into its parent. Title stayed within the same controlled group; no consideration-driven sale to a third party.

No other assignments are on record. Specifically, there is no transfer to a licensing LLC, no security-interest/securitization record, no release, and no change-of-name record post-dating the 2018 merger. Ownership of US 9,518,272 has thus rested continuously with the Protiva/Tekmira/Arbutus corporate family since filing.

(If Assignment Center shows zero additional entries beyond the two above, that is itself the finding: the original assignee's successor still owns the patent.)

Timeline diagram

timeline
    title Ownership of US 9518272
    2010 : Priority application filed by Protiva
    2016 : Continuation filed
         : Inventors assign rights to Protiva
         : US 9518272 issues
    2018 : Protiva amalgamated into Arbutus
    2022 : Arbutus and Genevant sue Moderna
    2023 : Arbutus and Genevant sue Pfizer and BioNTech

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT. The only recorded chain is Protiva Biotherapeutics → Arbutus Biopharma via merger (recorded 2018-02-20). Both are pre-clinical/clinical R&D biopharma organizations. There is no transfer to an "IP / Holdings / Licensing / Ventures" LLC, no single-purpose Delaware/Texas entity, and no registered-agent-service address anywhere in the chain.

2. Known asserter in the chain — NOT PRESENT. Neither the assignor (Protiva) nor the assignee of record (Arbutus Biopharma Corp, Nasdaq: ABUS) matches any of the enumerated NPE rosters (Acacia, Marathon, IV, IPNav, Wi-LAN, Conversant, Vringo, Pendrell, MPHJ, etc.). Arbutus is a publicly traded, SEC-reporting operating company with a disclosed HBV/virology pipeline.

3. Repeat correspondent across the chain — UNCLEAR / NOT VERIFIABLE. Could not retrieve correspondent of record for either entry (no reel/frame). No finding can be made.

4. Cascading transfers — NOT PRESENT. Two recorded events spanning ~7 years, one of which is an intra-group merger. No chained LLCs, no transfers in under 24 months, no shared correspondent addresses.

5. Pre-litigation transfer — NOT PRESENT. The last recorded transfer (2018-02-20 merger) precedes the first Arbutus/Genevant enforcement suit (Moderna, filed 2022-02-28) by roughly four years. The chain was not assembled to manufacture standing on the courthouse steps.

6. Bankruptcy fire-sale — NOT PRESENT. No Chapter 7/11 by Protiva, Tekmira, or Arbutus is in the record. Protiva's exit was a negotiated merger, not a distressed sale.

7. Privateering — PARTIAL / AMBIGUOUS (weak). Arbutus retains ownership and asserts jointly with its exclusive licensee Genevant Sciences GmbH, which holds the right to sublicense, practice, and sue for infringement in certain fields. The Moderna (D. Del. 1:22-cv-00252) and Pfizer/BioNTech (D.N.J. 3:23-cv-01876) complaints name Arbutus Biopharma Corporation as a co-plaintiff and owner, not as a hidden behind-the-scenes supplier. This is a licensing-partner enforcement model between genuine competitors in LNP technology, not the classic "operating company hides behind a shell NPE" privateering pattern. Note also that US 9,518,272 does not appear among the asserted patents in the Moderna set ('069, '359, '668, '435, '651, '378) or the Pfizer/BioNTech set ('651, '359, '378, '320, '098) that I could identify — so the '272 is a sibling in the same Arbutus LNP family rather than an asserted patent. Treat the privateering signal as weak and not attributable to this patent.

8. Defensive aggregator — NOT PRESENT. The chain does not terminate at RPX, AST, LOT, Unified Patents, or OIN. The patent is live and owned by an asserting party.

Additional note on the Google Patents litigation flag: The two dockets surfaced on the Google Patents record (S.D.N.Y. 1:22-cv-02229 and D.N.J. 3:23-cv-04200) are Acuitas Therapeutics Inc. v. Genevant Sciences GmbH et al., in which Arbutus is a defendant, not the plaintiff. Those suits concern other Arbutus patents ('651, '359, '378, '320, '098), and the S.D.N.Y. action was voluntarily dismissed; the D.N.J. action was dismissed 2024-05-20 for lack of subject-matter jurisdiction. This is a family-level litigation tag, not evidence that the '272 was asserted.

Verdict

Operating-company assertion.

The ownership chain is a clean two-step corporate succession — inventors → Protiva Biotherapeutics (recorded 2016-06-03), then Protiva → Arbutus Biopharma via merger (recorded 2018-02-20) — with no shell entity, no NPE assignee, no cascading LLC transfers, no pre-litigation transfer, and no bankruptcy sale anywhere in the record. The current owner is Protiva's corporate successor, Arbutus Biopharma Corporation, a Nasdaq-listed (ABUS), SEC-reporting biopharma that invented the claimed LNP technology and co-asserts its LNP patent family against actual competitors (Moderna; Pfizer/BioNTech) as a named party-plaintiff.

One honest caveat on category fit: the rubric for "Operating-company assertion" presumes the assignee ships products embodying the claims. Arbutus is clinical-stage and has no approved product on market, so that prong is not literally satisfied today. But because none of the NPE signals are present and the patent sits with a genuine research-based operating company that owns and litigates the technology, "Operating-company assertion" is the closest accurate classification — with the understanding that Arbutus monetizes its LNP patent estate substantially through licensing and enforcement rather than through a marketed product.

Verify: https://assignmentcenter.uspto.gov/ (search patent number 9518272) and https://patents.google.com/patent/US9518272B2/en — the reel/frame numbers and correspondent of record for the two entries above should be read directly from Assignment Center.

I'll research the prior art citations for US 9,518,272. Let me run several targeted searches.

I found key sources. Let me dig into the full "References Cited" list and the PTAB document.

Let me retrieve the full "References Cited" list from the patent's front page and the foreign patent documents.

I was unable to complete all planned lookups before hitting the tool-step limit, so I'll report what I verified and flag what remains open. Note on dates: the task header says the current date is April 26, 2026, while the environment banner says October 1, 2026 — I flag this discrepancy rather than silently resolving it.

Prior Art Analysis — U.S. Patent No. 9,518,272

A. Patent identification (verified)

Claim 1 (verbatim, as published): "A composition comprising: a plurality of nucleic acid‑lipid particles, wherein each particle in the plurality of particles comprises: (a) a nucleic acid; (b) a cationic lipid comprising from about 50 mol % to about 85 mol % of the total lipid present in the particle; (c) a non‑cationic lipid comprising from about 13 mol% to about 49.5 mol % of the total lipid present in the particle; and (d) a conjugated lipid that inhibits aggregation of particles comprising from about 0.5 mol % to about 10 mol % of the total lipid present in the particle, wherein at least about 95% of the particles in the plurality of particles have a non‑lamellar morphology."

Because priority is 2010‑06‑30, pre‑AIA 35 U.S.C. § 102 governs. The critical § 102(b) grace date is therefore on/about 2009‑06‑30; § 102(a)/(e) key off the 2010‑06‑30 priority date. The § 102(a)/§ 102(e) window is what matters most here.

B. Methodology / limitation flagged up front

I could not retrieve a complete, verbatim front‑page "References Cited" listing from USPTO PatentCenter (my searches returned a truncated FreePatentsOnline list and a PTAB document whose reference list only partially overlaps). The list below is assembled from the FreePatentsOnline record for 9518272 (https://www.freepatentsonline.com/9518272.html) plus corroborating Google Patents / Justia records. Treat the enumeration as high‑confidence but verify against the granted front page before relying on it as exhaustive.

A crucial analytical point that drives the whole analysis:

Most of the "US Patent References" cited on the '272 face are the applicant's OWN same‑family continuations (Yaworski et al., Protiva/Arbutus). They are not § 102 prior art to the '272 patent because they share the same inventive entity and the same 2010 priority chain. Only the independently‑derived, earlier‑published references can actually anticipate.

C. The "References Cited" list and § 102 assessment

C‑1. The one reference that actually matters — and it already killed a sibling patent

★ U.S. Patent No. 8,058,069 B2 — "Lipid formulations for nucleic acid delivery," Yaworski et al.

• Full citation / dates: U.S. 8,058,069, filed 2009‑04‑15 (Ser. No. 12/424,367), issued 2011‑11‑15; published as US 2010/0130588 A1 on 2010‑05‑27; benefit of provisional 61/045,228 (2008‑04‑15).
• Description: Discloses stable nucleic acid‑lipid particles (SNALP) comprising an siRNA, a cationic lipid, a non‑cationic lipid, and a conjugated (PEG) lipid, including the 2:30, 2:40, 1:57 and 1:62 formulations and the Direct Dilution Method; charactered by size, polydispersity, encapsulation and (per the PTAB record) particle morphology.
• § 102 exposure: § 102(e)(2) (issued U.S. patent) and § 102(a) (the 2010‑05‑27 publication predates the 2010‑06‑30 priority). Because '069 was found to have a different inventive entity from the '272‑family (MacLachlan, Yaworski, Lam, Jeffs, Palmer vs. Yaworski, Jeffs, Palmer), it is available as § 102 art notwithstanding common ownership (common ownership defeats only § 103 via § 103(c), not § 102).
• Claims potentially anticipated: Claim 1 (the composition claim) — the PTAB and Federal Circuit reasoning is directly on point: the '069 patent discloses the "same or essentially the same" formulations and processes, so the recited "≥95% non‑lamellar morphology" is the "natural result" and therefore inherent — anticipating rather than merely rendering obvious. Dependent claims reciting specific cationic lipids (DLinDMA/"XTC2"), cholesterol, PEG‑lipids, and the named formulations would fall with claim 1.

This is not hypothetical. In IPR2018‑00680, the PTAB held all claims of the sibling U.S. 9,404,127 unpatentable as inherently anticipated by U.S. 8,058,069, and the Federal Circuit affirmed in Arbutus Biopharma Corp. v. ModernaTX, Inc., No. 2020‑1183 (Fed. Cir. Apr. 11, 2023). The '272 patent shares the same "non‑lamellar morphology" limitation and the same priority chain, so U.S. 8,058,069 is the single most relevant § 102 reference and the natural vehicle for any future IPR against '272.

C‑2. The remaining cited references, ranked by § 102 usefulness

C‑3. Older "References Cited" (flag: placement unverified)

A PTAB document carrying the family title "NON‑LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY" lists an older set of cited U.S. patents — Szoka 4,394,448; Weder 4,438,052; Deamer 4,515,736; Papahadjopoulos 4,598,051; Eppstein 4,897,355 & 5,208,036 & 5,545,412; Woodle 5,013,556; Behr 5,171,678; Martin 5,225,212; Felgner 5,264,618 & 5,703,055; Rose 5,279,833; Epand 5,283,185; Eley 5,320,906; Gebeyehu 5,334,761; Jesse 5,578,475; Shih 5,627,159; Debs 5,641,662; Busch 5,656,743; Haces 5,674,908; Bally 5,705,385; Hawley‑Nelson 5,736,392; Choi 5,820,873; Schwartz 5,877,220; Holland 5,885,613; Dwyer 5,958,901; Wheeler 5,976,567 & 5,981,501 — plus an NPL citation to Aprieco, S., et al. These are background liposome/gene‑transfer art, mostly published well before 2008–2009 (§ 102(b)). They provide at most § 103 context (e.g., DOPE/cholesterol/PEG‑lipid SNALP architecture) — I could not verify whether this list sits on the '272 front page or on a sibling ('127/'417), so treat its attribution as unconfirmed.

D. Bottom line

1. Most relevant § 102 prior art: U.S. 8,058,069 (and its publication US 2010/0130588 A1, pub. 2010‑05‑27). It is the reference that anticipated the sibling U.S. 9,404,127 in IPR2018‑00680 (affirmed, Arbutus v. ModernaTX, 2020‑1183 (Fed. Cir. 2023)), and its rationale — same formulations + same process ⇒ the "≥95% non‑lamellar" limitation is the inherent "natural result" — maps directly onto '272 claim 1 and its formulation‑dependent claims.
2. Same‑family citations ('417, '127, and the Yaworski published applications) are not § 102 art because of shared inventive entity/priority.
3. US 8,492,359, 8,822,668, 8,283,333 share the '069 disclosure but likely fail § 102(e) against the 2010‑06‑30 priority because they were filed later; they are corroborative, not independent, art.
4. The remaining cited references (Heyes, MacLachlan siRNA patents, Chu, Cullis, etc.) are best characterized as § 102(e)/§ 103 art for dependent‑claim features (cationic‑lipid species, modified siRNAs, payloads), not for the core composition claim.

E. Explicit caveats (per the "do not fabricate" rule)

• Claim text: claim 1 is reproduced from a secondary source quoting the granted claim; verify at USPTO PatentCenter.
• Completeness of the cited‑reference list: the enumeration is not verified as exhaustive; the FPO page I retrieved was truncated and the older‑reference block's assignment to '272 is unconfirmed.
• Effective dates: I did not independently verify filing dates for Heyes '256, Chu '827, Cullis 2012/0276209, etc.; their § 102(e) status against the 2010‑06‑30 date is timing‑dependent and unverified.
• I did not auto‑correct any identifier; the numbers above are reported literally as they appeared in the cited records. (I again note that a "9518272" hit in GB priority data of US 5,958,710 is a UK priority number, not this patent, and is excluded.)

I'll build on the prior sections, but first I need to ground the obviousness analysis in the actual prior-art references and the claim text. Let me run targeted searches.

Excellent grounding. Let me now pin down the '272 claim text and the outcome of the related IPRs, plus the non-lamellar/HII-phase prior art.

Obviousness Analysis — U.S. Patent No. 9,518,272 ("the '272 patent")

0. Threshold notes, consistency flags, and a caveat carried forward

Date flag (minor). The earlier sections were generated with "Today's date: 2026‑10‑01." This task header says "Current Date: April 26, 2026." I use the substance of the prior sections unchanged; the date discrepancy does not affect the analysis (no post‑2023 art is relevant to a 2010‑priority claim).

Claim-text caveat (carried forward, unchanged). As the Patent Summary section flagged, the verbatim granted text of the '272 claims was not retrieved from an authoritative full‑text source. The reconstruction of claim 1 below is now better corroborated than before: the same range language (“a cationic lipid comprising from 50 mol % to 85 mol %... a non-cationic lipid comprising from 13 mol % to 49.5 mol %,” and “greater than 95% of the [particles] have a non‑lamellar morphology”) appears verbatim in later members of the same Arbutus family (US 2022/0226453 A1; US 2024/0182895 A1), which track the '272 disclosure. Confidence in the substance of claim 1 is now moderate‑to‑high; confidence in exact wording/claim numbering remains moderate. Verify against USPTO PatentCenter before relying on it.

No contradiction with the prior sections. The prior "Patent summary" reconstructed independent claim 1 as a composition with the 50–85 / 13–49.5 / 0.5–10 mol% ranges plus the ≥95% non‑lamellar ("Morphology") limitation. That matches the '272 specification's Summary of the Invention verbatim. One refinement worth stating explicitly: the '272 recites numeric mol% ranges in the claim itself (unlike sibling U.S. 9,404,127, whose claim 1 recites only "a cationic lipid," "a non‑cationic lipid," "a conjugated lipid," plus the Morphology Limitation). That distinction matters for § 103, as discussed in § 6.

Assumed claim 1 (the analysis vehicle):

1. A composition comprising a plurality of nucleic acid‑lipid particles, wherein each particle in the plurality of particles comprises: (a) a nucleic acid; (b) a cationic lipid comprising from about 50 mol % to about 85 mol % of the total lipid present in the particle; (c) a non‑cationic lipid comprising from about 13 mol % to about 49.5 mol % of the total lipid present in the particle; and (d) a conjugated lipid that inhibits aggregation of particles comprising from about 0.5 mol % to about 10 mol % of the total lipid present in the particle, wherein at least about 95% of the particles in the plurality of particles have a non‑lamellar morphology.

1. The § 103 framework that governs (and why "new morphology" does little work here)

For a 2010‑priority, AIA‑filed patent (application 15/153,487 filed 2016‑05‑12), obviousness is assessed under AIA 35 U.S.C. § 103 with the Graham v. John Deere factors: scope/content of the prior art, differences, PHOSITA level, and secondary considerations. Note the AIA effective‑filing‑date mechanics because they drive which references qualify:

• If the '272 is entitled to its June 30, 2010 provisional priority, the art universe is pre‑2010‑06‑30.
• Pre‑AIA § 102(e)/AIA § 102(a)(2) art that is commonly owned with the claimed invention is excepted from prior art (AIA § 102(b)(2)(C); pre‑AIA § 103(c)). The '069 patent and several Arbutus/Protiva references are commonly owned by Protiva/Arbutus — this is the same disqualification Patent Owner successfully invoked against the '069 in the '127 IPR (IPR2018‑00680).
• § 102(a)(1) art (printed publications/patents published more than one year before filing) is not subject to the common‑ownership exception. So robust § 103 grounds should lean on § 102(a)(1) references (e.g., WO 2005/007196, US 2006/0134189) where the '069 is vulnerable.

Key doctrine. A claim to a composition defined partly by a property that is the "natural result flowing from" a known process/known composition cannot be saved by newly discovering that property (Schering v. Geneva; Bristol‑Myers Squibb v. Ben Venue ("newly discovered results of known processes directed to the same purpose are not patentable because such results are inherent"); Atlas Powder). The Federal Circuit applied exactly this logic to the '272's sibling in Arbutus Biopharma Corp. v. ModernaTX, Inc., No. 2020‑1183 (Fed. Cir. Apr. 11, 2023) — affirming that the Morphology Limitation was inherently disclosed by the '069 patent and specifically holding that where the art discloses "the same formulations and the same DDM," the claimed morphology is a "natural result." That reasoning is directly transferable to '272's claim 1.

2. The prior‑art universe (dates, content, §-status)

Sources: Google Patents US9518272B2 (https://patents.google.com/patent/US9518272/en); '069 claim/spec at RPX (https://insight.rpxcorp.com/patent/US8058069B2); IPR2018‑00680 FWD and Petition (https://www.bigmoleculewatch.com/wp-content/uploads/sites/2/2023/12/PTAB-IPR2018-00680-Final-Written-Decision.pdf; .../PTAB-IPR2018-00680-Petition.pdf); Fed. Cir. 20‑1183 opinion (https://cafc.uscourts.gov/opinions-orders/20-1183.OPINION.4-11-2023_2108936.pdf).

3. Ground 1 — The '069 patent alone renders claim 1 obvious

Every element of assumed claim 1 maps onto the '069's specification:

• (a) nucleic acid (siRNA; ApoB siRNA disclosed) — '069 discloses this.
• (b) cationic lipid 50–85 mol% — the '069 specification expressly recites "from about 50 mol % to about 85 mol %" (quoted in the IPR2018‑00680 briefing at '069 col. 3:12–15).
• (c) non‑cationic lipid 13–49.5 mol% — '069 specification expressly recites "from about 13 mol % to about 49.5 mol %" (col. 3:14–16).
• (d) conjugated lipid 0.5–10 mol% — '069 claims 0.5–2 mol%; the family's own 10:15 formulation carries 10 mol% PEG‑C‑DMA; the '272 itself places its 7:54/7:58 formulations at ~5–10 mol% PEG‑lipid. The 0.5–10 range is squarely within the prior art disclosure.
• ≥95% non‑lamellar morphology — the only element not expressly recited. Under Arbutus v. ModernaTX, it is inherent: the '069 discloses the same formulations (1:57, 1:62), and both the '069 and the '272 direct the POSITA to the same '031 publication for DDM. Making the disclosed formulation by DDM "naturally results" in non‑lamellar morphology (the Fed. Cir. noted there were only "five formulations and two processes").

Motivation / reasonable expectation of success. The '069 and the '272 share inventors (Yaworski, Jeffs, Palmer), assignee, field, and purpose (serum‑stable SNALP for in vivo siRNA delivery). A POSITA optimizing gene silencing would (i) use the '069's disclosed formulations, (ii) use the DDM disclosed in the '031, and (iii) thereby arrive at the claimed particles. KSR predictability and "obvious to try" support the conclusion; the patent's own admission that "the presence of certain molar ratios of lipid component... results in improved or enhanced activity" concedes that lipid ratios are a result‑effective variable subject to routine optimization (In re Boesch; In re Antonie).

Range‑law overlay. Where the prior art expressly discloses a range and the claim recites a narrower range within it, there is a presumption of obviousness (In re Peterson; In re Woodruff) — the patentee must show criticality. Here the '069's explicit 50–85 / 13–49.5 ranges overlap/encompass the '272's ranges, so the presumption attaches directly (unlike the situation in IPR2019‑00554, where the PTAB declined to apply the presumption because the phospholipid range was only derived indirectly — see § 7).

4. Ground 2 — '069 in view of the '613 patent (for the Morphology Limitation, framed as § 103)

If one treats the ≥95% non‑lamellar limitation as not strictly inherent, it is still obvious:

• The '613 patent expressly teaches that the three‑dimensional structure (lamellar vs. non‑lamellar) of nucleic‑acid–lipid particles is "related to [their] fusogenicity and, potentially, efficacy," that lipid combinations "promote HII [non‑lamellar] phase formation," and that particle populations can be "entirely non‑lamellar." (This is precisely the combination Moderna advanced in IPR2018‑00680's alternative § 103 theory.)
• Motivation: a POSITA seeking higher transfection/silencing efficiency would select formulations and processes favoring the non‑lamellar/HII phase, consistent with the '069's stated goal of having nucleic acid "encapsulated within the lipid portion of the lipid particle."
• Reasonable expectation: the '613's express teaching that non‑lamellar phases can be induced, plus the '031's DDM parameters, make achievement of >95% non‑lamellar a matter of routine optimization of six disclosed variables (the '272 spec's own Table 1 parameter list).

5. Ground 3 — '196 PCT / '189 primary reference (a § 102(a)(1) path around ordinary‑ownership disqualification) + '658 / '565 / '027 / '613

Because the '069 may be excepted as § 102(a)(2)/(e) art by common ownership, a resilient § 103 case uses § 102(a)(1) references:

1. '196 PCT / '189 publication as primary: disclose four‑component nucleic‑acid‑lipid particles with overlapping mol% ranges for cationic, non‑cationic, and conjugated lipids, and disclose DDM.
2. '658 patent: same lipids + 2:30/2:40 formulations + "a direct dilution process."
3. '565 patent: 2:30 formulation with the exact lipid set (PEG‑cDMA/DLinDMA/DSPC/cholesterol) and an siRNA payload.
4. '613: non‑lamellar phase ↔ efficacy.
5. '031 / '025: DDM and SDM, incorporated for enablement.

Motivation to combine (common to Grounds 1–3):

• Same field, same problem: all address serum‑stable nucleic‑acid–lipid delivery; the field was crowded and cumulative.
• Known design space: cationic‑lipid mol% was recognized as tunable and there was a documented trend toward >50 mol% (the '272's own prosecution/related IPRs note that the upper end of disclosed 2–60% and 40–50% ranges overlap the claimed 50–85%; the '189 states it is "more preferable" to have enough cationic lipid to neutralize ≥90% of nucleic‑acid charge).
• Predictable variation: adjusting mol% of cationic/non‑cationic/conjugated lipid to balance charge neutralization, serum stability, and size is the classic "result‑effective variable."
• Tie‑in by incorporation: the '272 itself incorporates the '031 and '025 publications "in their entirety for all purposes" for the two processes — so the process disclosures are effectively admitted art.

6. Ground 4 — Dependent claims

The dependent claims add: specific cationic lipids (DLinDMA, DLin‑K‑C2‑DMA/"XTC2," MC3, LenMC3, MC3 Ether/Amide, Pan‑MC3/4/5); non‑cationic lipids (cholesterol/derivatives; DPPC/DSPC/DOPE); PEG‑DAA/PEG‑CDMA conjugates; 2′OMe‑, 2′F‑, MOE‑, LNA‑modified siRNA; specific 1:57, 1:62, 7:54, 7:58 formulations; and the HII/cubic characterization.

• Specific lipid species (DLinDMA, DSPC, cholesterol, PEG‑C‑DMA) are taught by the '069, '565, '658, '027, and '189.
• 7:54 / 7:58 formulations (7 mol% PEG, 54/58 mol% cationic lipid) fall within claim 1 and are disclosed in the Arbutus publication line (US 2011/0195127 A1: "the kits... comprise a 15:7, 1:62, 7:54, or 7:58...").
• Modified siRNAs (2′OMe) were routine and known to reduce immunostimulation while retaining RNAi activity — obvious to try with a reasonable expectation of success.
• HII/cubic structure (dependent claim) is again an inherent/known property (the '613; Safinya/Koltover). Note the PTAB in IPR2018‑00680 initially questioned a conclusory inherency showing for the HII claim but the Federal Circuit ultimately upheld inherent anticipation of the HII claim on the "three‑dimensional structures" evidence.

7. Secondary considerations (and why they likely fail to rebut)

8. Counterarguments a Patent Owner would raise (and the response)

1. Common‑ownership disqualification (§ 102(b)(2)(C) / § 103(c)). Patent Owner successfully argued this against the '069 in the '127 IPR. Response: (a) it does not disqualify the '069 from anticipation (the '127 was nonetheless held anticipated); (b) it does not reach § 102(a)(1) art — the '196 PCT, '189, '613, the 1998 Science paper, and other pre‑2009 publications remain available; (c) a petitioner could argue the '272's June 2010 priority is not fully supported for the claimed ranges (written‑description risk), pushing the effective filing date to 2016 and converting the '069 (issued 2011) into § 102(a)(1)/(b) art not subject to the exception.
2. "Non‑lamellar ≥95%" is not necessarily present (no true inherency). Arbutus argued (and offered Dr. Heyes's Cryo‑TEM study) that DDM does not "inevitably" yield >95% non‑lamellar in every instance (the study reported ~22–31% non‑lamellar for certain '069 formulations even by direct dilution — IPR2018‑00680 Record). Response: the Fed. Cir. rejected that framing for the '127, holding anticipation requires the limitation be met "to the same extent as the patented invention," and the '272 provides no more than the same Cryo‑TEM characterization.
3. Presumption‑of‑obviousness does not apply to an implicit range. Patent Owner will cite the PTAB's IPR2019‑00554 FWD, which declined to apply the Dupont/Peterson presumption where a claimed sub‑component range (phospholipid 4–10%) was not expressly disclosed but only derived. Response: distinguishable for the '272 — the claimed cationic (50–85) and non‑cationic (13–49.5) ranges are expressly disclosed in the '069 specification, and the conjugated‑lipid 0.5–10% range is expressly met by the 10:15 formulation (10 mol% PEG).
4. Unpredictability of LNP morphology. Arbutus may argue morphology/efficacy in LNP systems is unpredictable, defeating "reasonable expectation of success." Response: KSR allows combination where the art provides a "finite number of identified, predictable solutions" — here, five formulations × two processes, exactly what the Fed. Cir. called a "limited number of tools."

(Caveat: I could not confirm the ultimate disposition of IPR2019‑00554 (the challenge to the '069 itself) within the available search results. The RPX listing shows the '069 as "DC CAFC," which I read as a cancelled‑/disclaimed‑type status but cannot verify; treat the '069's current claim status as unconfirmed and rely on it only as prior‑art disclosure, not as a live patent.)

9. Bottom line

• Strongest § 103 ground: U.S. 8,058,069 alone, or '069 + '613. Every element of '272 claim 1 is disclosed in the '069 specification (including the exact 50–85 and 13–49.5 mol% ranges) or is an inherent "natural result" of the '069's formulations processed by the DDM disclosed in the same '031 publication — the precise holding of Arbutus v. ModernaTX applied to a sibling patent with an overlapping disclosure.
• Most defensible ground (bulletproof against the common‑ownership objection): '196 PCT / '189 publication as primary + '658 + '565 + '613 + '031, using express overlapping ranges + the known trend toward >50 mol% cationic lipid + the known non‑lamellar↔efficacy relationship.
• Overall strength: On the present record I assess claim 1 as highly likely obvious (§ 103) and quite plausibly anticipated (§ 102) on the '069 disclosure, subject to (i) the common‑ownership prior‑art exception and (ii) confirmation of the actual granted claim text and the '069's art status.
• Confidence: Moderate‑to‑high on the technical mapping; moderate on claim wording and on any specific § 102/§ 103 outcome given the unresolved common‑ownership and IPR‑status questions. The one point I would escalate before any filing is a verbatim pull of the '272 granted claims and the docket status of IPR2019‑00554.

Primary sources: https://patents.google.com/patent/US9518272/en; https://insight.rpxcorp.com/patent/US8058069B2; https://cafc.uscourts.gov/opinions-orders/20-1183.OPINION.4-11-2023_2108936.pdf; IPR2018‑00680 FWD/Petition and IPR2019‑00554 FWD/Petition (bigmoleculewatch.com PTAB archive); Akin Gump and Finnegan case summaries (akingump.com, finnegan.com).